



## **Annemiläi Tijeras-Raballand, PhD**

Annemiläi Tijeras-Raballand is CEO of AFR Oncology. She studied Cellular Biology, Physiology, and Pathology at the University Denis Diderot of Paris where she received her master and PhD in 2007 and 2010, respectively. After finishing her PhD, she joined AFR Oncology (ex AAREC Filia Research) as a project manager with a focus on liver, head & neck, and renal tumor. AFR Oncology is a clinical research organization involved in new drugs development, drugs repositioning, and translational research on biomarkers (Early phase to phase III trial).

Dr Tijeras-Raballand has been involved in preclinical and translational research on several inhibitors targeting c-MET, TGF beta, Notch, and VEGFR pathways. To address these issues, she participated to the development of the molecular biology and the immunohistology platforms. In addition, she participated to the setup of the culture of precision-cut human tumor slices as a dedicated tool for research and evaluation of novel anticancer drugs. She was head of AFR Oncology laboratory in 2015 before becoming CEO in 2017.

### *Selected references:*

- Further pharmacological and genetic evidence for the efficacy of PIGF inhibition in cancer and eye disease. Tijeras-Raballand et al., 2010, Cell
- Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Tijeras-Raballand et al., 2012, Targeted Oncology
- Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Serova et al., 2015, Oncotarget
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. André et al., 2015, JCO
- Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Serova et al., 2016, Oncotarget